FCMI
ABEO icon

Foresite Capital Management III’s Abeona Therapeutics ABEO Stock Holding History

Foresite Capital Management III’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-733
Closed -$117K – 21
2017
Q2 		$117K Buy
+733
New +$100K 0.04% 26

Other funds holding ABEO

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CHP
Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Foresite Capital Management III's ABEO Position: Q3 2017 in Review

Foresite Capital Management III sold out of Abeona Therapeutics (ABEO) in Q3 2017, closing a stake of 733 shares — an estimated $117K sold.

Foresite Capital Management III first reported a position in ABEO in Q2 2017 and held it in 1 quarter. The position peaked at $117K in Q2 2017. 75 funds tracked by Wall St. Rank hold ABEO as of Q3 2017.

  • Foresite Capital Management III reported no remaining Abeona Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Foresite Capital Management III sold 733 Abeona Therapeutics shares in Q3 2017, an estimated $117K.
  • Foresite Capital Management III first reported a position in Abeona Therapeutics in Q2 2017 and held it in 1 quarter.
  • Foresite Capital Management III's Abeona Therapeutics position peaked at $117K in Q2 2017.
  • 75 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2017.

Based on Foresite Capital Management III's 13F filing for Q3 2017, filed 13 Nov 2017.